File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.4049/jimmunol.173.5.2933
- Scopus: eid_2-s2.0-4344659974
- PMID: 15322151
- WOS: WOS:000223529800013
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease
Title | CD30/CD30 ligand (CD153) interaction regulates CD4<sup>+</sup> T cell-mediated graft-versus-host disease |
---|---|
Authors | |
Issue Date | 2004 |
Citation | Journal of Immunology, 2004, v. 173, n. 5, p. 2933-2941 How to Cite? |
Abstract | CD30, a TNFR family member, is expressed on activated CD4+ and CD8+ T cells and B cells and is a marker of Hodgkin's lymphoma; its ligand, CD30L (CD153) is expressed by activated CD4+ and CD8 + T cells, B cells, and macrophages. Signaling via CD30 can lead to proliferation or cell death. CD30-deficient (-/-) mice have impaired thymic negative selection and increased autoreactivity. Although human alloreactive T cells preferentially reside within the CD30+ T cell subset, implicating CD30 as a regulator of T cell immune responses, the role of CD30/CD153 in regulating graft-vs-host disease (GVHD) has not been reported. We used a neutralizing anti-CD153 mAb, CD30-/- donor mice, and generated CD153-/- recipient mice to analyze the effect of CD30/CD153 interaction on GVHD induction. Our data indicate that the CD30/CD153 pathway is a potent regulator of CD4+, but not CD8+, T cell-mediated GVHD. Although blocking CD30/CD153 interactions in vivo did not affect alloreactive CD4+ T cell proliferation or apoptosis, a substantial reduction in donor CD4+ T cell migration into the gastrointestinal tract was readily observed with lesser effects in other GVHD target organs. Blockade of the CD30/CD153 pathway represents a new approach for preventing CD4+ T cell-mediated GVHD. |
Persistent Identifier | http://hdl.handle.net/10722/291823 |
ISSN | 2023 Impact Factor: 3.6 2023 SCImago Journal Rankings: 1.558 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Blazar, Bruce R. | - |
dc.contributor.author | Levy, Robert B. | - |
dc.contributor.author | Mak, Tak W. | - |
dc.contributor.author | Panoskaltsis-Mortari, Angela | - |
dc.contributor.author | Muta, Hiromi | - |
dc.contributor.author | Jones, Monica | - |
dc.contributor.author | Roskos, Melinda | - |
dc.contributor.author | Serody, Jonathan S. | - |
dc.contributor.author | Yagita, Hideo | - |
dc.contributor.author | Podack, Eckhard R. | - |
dc.contributor.author | Taylor, Patricia A. | - |
dc.date.accessioned | 2020-11-17T14:55:11Z | - |
dc.date.available | 2020-11-17T14:55:11Z | - |
dc.date.issued | 2004 | - |
dc.identifier.citation | Journal of Immunology, 2004, v. 173, n. 5, p. 2933-2941 | - |
dc.identifier.issn | 0022-1767 | - |
dc.identifier.uri | http://hdl.handle.net/10722/291823 | - |
dc.description.abstract | CD30, a TNFR family member, is expressed on activated CD4+ and CD8+ T cells and B cells and is a marker of Hodgkin's lymphoma; its ligand, CD30L (CD153) is expressed by activated CD4+ and CD8 + T cells, B cells, and macrophages. Signaling via CD30 can lead to proliferation or cell death. CD30-deficient (-/-) mice have impaired thymic negative selection and increased autoreactivity. Although human alloreactive T cells preferentially reside within the CD30+ T cell subset, implicating CD30 as a regulator of T cell immune responses, the role of CD30/CD153 in regulating graft-vs-host disease (GVHD) has not been reported. We used a neutralizing anti-CD153 mAb, CD30-/- donor mice, and generated CD153-/- recipient mice to analyze the effect of CD30/CD153 interaction on GVHD induction. Our data indicate that the CD30/CD153 pathway is a potent regulator of CD4+, but not CD8+, T cell-mediated GVHD. Although blocking CD30/CD153 interactions in vivo did not affect alloreactive CD4+ T cell proliferation or apoptosis, a substantial reduction in donor CD4+ T cell migration into the gastrointestinal tract was readily observed with lesser effects in other GVHD target organs. Blockade of the CD30/CD153 pathway represents a new approach for preventing CD4+ T cell-mediated GVHD. | - |
dc.language | eng | - |
dc.relation.ispartof | Journal of Immunology | - |
dc.title | CD30/CD30 ligand (CD153) interaction regulates CD4<sup>+</sup> T cell-mediated graft-versus-host disease | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.4049/jimmunol.173.5.2933 | - |
dc.identifier.pmid | 15322151 | - |
dc.identifier.scopus | eid_2-s2.0-4344659974 | - |
dc.identifier.volume | 173 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 2933 | - |
dc.identifier.epage | 2941 | - |
dc.identifier.isi | WOS:000223529800013 | - |
dc.identifier.issnl | 0022-1767 | - |